Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?

JEREMİC, Branislav; FİLİPOVİC, Nenad; DUBİNSKY, Pavol; ÖZYİĞİT, Gökhan

Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?

Branislav JEREMİC, (Department of Oncology, Bio IRC)

Pavol DUBİNSKY, (Department of Radiation Oncology, East Slovakia Institute of Oncology)

Nenad FİLİPOVİC, (Department of Oncology, Bio IRC)

Gökhan ÖZYİĞİT (Hacettepe Üniversitesi)

Türk Onkoloji Dergisi

1 1

Yıl: 2019 Cilt: 34 Sayı: 2 Sayfa Aralığı: 133 - 136 Metin Dili: İngilizce İndeks Tarihi: 04-05-2020

Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?

Öz:

Here we present a summary of existing evidence from meta-analyses and systematic reviews in thesetting of locally advanced, inoperable squamous cell cancer of the head and neck, treated with radicalradiotherapy and concurrent cisplatin therapy either weekly or every 3 weeks. Taken together, the dataseem to indicate that there is no difference in major outcomes, including toxicity. However, caution inthe interpretation of the data should be exercised due to poor quality of original studies, none of whichwas a prospective randomized phase III trial. Practicing clinicians should continue using their best judgment about the most appropriate treatment option in this setting, taking into account both the existingevidence and also various patient and tumor characteristics.

Anahtar Kelime:

Konular: Onkoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Pignon JP, le Maître A, Maillard E, Bourhis J; MACHNC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4–14.
2. Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw 2017;15(6):761–70.
3. Ang KK, Chen A, Curran WJ Jr, Garden AS, Harari PM, Murphy BA, et al. Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). Cancer 2012;118(23):5783–92.
4. Guan J, Zhang Y, Li Q, Zhang Y, Li L, Chen M, et al. A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC). Oncotarget 2016;7(43):70185–70193.
5. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Weekly Low-Dose Versus Three- -Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. Oncologist 2017;22(9):1056–66.
6. Jacinto JK, Co J, Mejia MB, Regala EE. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. Br J Radiol 2017;90(1079):20170442.
7. Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, et al. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Head Neck 2019;41(5):1490–8.
8. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Front Oncol 2019;9:86.
9. Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986;39(2):136–44.
10.Bartelink H, Kallman RF, Rapacchietta D, Hart GA. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation. Radiother Oncol 1986;6(1):61–74.
11. Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr, Bossi P, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck 2016;38 Suppl 1:E2151–8.
12.Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997;43(1):29–37.
13.Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18(7):1458–64.
14.Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24–35.
15.Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 2012;22(2):128–42.
16.Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32(27):2940–50.

APA	JEREMİC B, DUBİNSKY P, FİLİPOVİC N, ÖZYİĞİT G (2019). Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. , 133 - 136.
Chicago	JEREMİC Branislav,DUBİNSKY Pavol,FİLİPOVİC Nenad,ÖZYİĞİT Gökhan Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. (2019): 133 - 136.
MLA	JEREMİC Branislav,DUBİNSKY Pavol,FİLİPOVİC Nenad,ÖZYİĞİT Gökhan Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. , 2019, ss.133 - 136.
AMA	JEREMİC B,DUBİNSKY P,FİLİPOVİC N,ÖZYİĞİT G Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. . 2019; 133 - 136.
Vancouver	JEREMİC B,DUBİNSKY P,FİLİPOVİC N,ÖZYİĞİT G Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. . 2019; 133 - 136.
IEEE	JEREMİC B,DUBİNSKY P,FİLİPOVİC N,ÖZYİĞİT G "Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?." , ss.133 - 136, 2019.
ISNAD	JEREMİC, Branislav vd. "Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?". (2019), 133-136.

APA	JEREMİC B, DUBİNSKY P, FİLİPOVİC N, ÖZYİĞİT G (2019). Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. Türk Onkoloji Dergisi, 34(2), 133 - 136.
Chicago	JEREMİC Branislav,DUBİNSKY Pavol,FİLİPOVİC Nenad,ÖZYİĞİT Gökhan Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. Türk Onkoloji Dergisi 34, no.2 (2019): 133 - 136.
MLA	JEREMİC Branislav,DUBİNSKY Pavol,FİLİPOVİC Nenad,ÖZYİĞİT Gökhan Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. Türk Onkoloji Dergisi, vol.34, no.2, 2019, ss.133 - 136.
AMA	JEREMİC B,DUBİNSKY P,FİLİPOVİC N,ÖZYİĞİT G Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. Türk Onkoloji Dergisi. 2019; 34(2): 133 - 136.
Vancouver	JEREMİC B,DUBİNSKY P,FİLİPOVİC N,ÖZYİĞİT G Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?. Türk Onkoloji Dergisi. 2019; 34(2): 133 - 136.
IEEE	JEREMİC B,DUBİNSKY P,FİLİPOVİC N,ÖZYİĞİT G "Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?." Türk Onkoloji Dergisi, 34, ss.133 - 136, 2019.
ISNAD	JEREMİC, Branislav vd. "Optimal Administration Frequency of Cisplatin Concurrently With Radical Radiotherapy in the Definitive Treatment of Locally Advanced, Inoperable Squamous Cell Cancer of the Head and Neck. Still Obscured by Clouds?". Türk Onkoloji Dergisi 34/2 (2019), 133-136.